CVRx (CVRX)
NASDAQ:CVRX
Want to see CVRX full AI Analyst Report?
CVRX Stock Chart & Stats
$7.36
-$0.03(-0.21%)
At close: 4:00 PM EST
$7.36
-$0.03(-0.21%)
Day’s Range― - ―
52-Week Range$4.37 - $11.30
Previous CloseN/A
Volume20.10K
Average Volume (3M)197.28K
Market Cap
$133.48M
Enterprise Value$134.80M
Total Cash (Recent Filing)$72.30M
Total Debt (Recent Filing)$59.40M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Aug 04, 2026EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding26,535,944
10 Day Avg. Volume162,574
30 Day Avg. Volume197,283
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)4.71
Price to Sales (P/S)3.27
P/FCF Ratio-4.54
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue2.28
Enterprise Value/Gross Profit2.67
Enterprise Value/Ebitda-2.93
Forecast
1Y Price Target
$10.50Price Target Upside42.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.96
Revenue Forecast (FY)$65.34M
Bulls Say, Bears Say
Bulls Say
High Gross Margin & Favorable ASPSustained ~85–87% gross margins and rising ASP demonstrate strong product-level economics and manufacturing efficiency. These unit economics provide durable contribution margin as volumes scale, making profitability achievable if fixed operating costs are controlled and commercial adoption continues.
Commercial Traction And Revenue GrowthConsistent mid-teens to 20% revenue growth and expanding implanting centers and territories reflect durable commercial rollout. A growing installed-base and broader sales footprint lower per-account acquisition costs and signal increasing clinical adoption that can compound revenue over multiple quarters.
Structural Reimbursement Progress (Category I CPT)Category I CPT coding is a lasting reimbursement advancement that reduces billing friction and supports hospital adoption. Improved MA approval rates indicate fewer payer barriers over time, enhancing procedure economics and making the therapy more accessible to eligible patients on an ongoing basis.
Bears Say
Persistent Negative Operating Cash FlowSustained operating cash burn converts accounting losses into real liquidity pressure, reducing runway and forcing reliance on financing. Persistent negative FCF limits the firm's ability to self-fund expansion or absorb reimbursement timing shocks without dilutive or debt financing, raising long-term execution risk.
Rising Leverage And Compressed EquityMaterial increase in leverage and a thinner equity cushion reduce financial flexibility and increase refinancing and interest-rate sensitivity. Higher debt levels can constrain strategic options, elevate fixed costs, and amplify downside in adverse commercial or reimbursement scenarios over the medium term.
High Opex And Long Timeline To Realize Trial-driven TAMLarge ongoing operating expenses materially exceed near-term revenue guidance, sustaining losses and cash burn. Meanwhile, the BENEFIT-HF trial that could materially expand TAM has a multi-year timeline, meaning the pathway to meaningfully higher sustainable revenues is long and financing-dependent.
CVRx News
CVRX FAQ
What was CVRx’s price range in the past 12 months?
CVRx lowest stock price was $4.37 and its highest was $11.30 in the past 12 months.
What is CVRx’s market cap?
CVRx’s market cap is $133.48M.
When is CVRx’s upcoming earnings report date?
CVRx’s upcoming earnings report date is Aug 04, 2026 which is in 49 days.
How were CVRx’s earnings last quarter?
CVRx released its earnings results on May 11, 2026. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.504 by $0.004.
Is CVRx overvalued?
According to Wall Street analysts CVRx’s price is currently Undervalued.
Does CVRx pay dividends?
CVRx does not currently pay dividends.
What is CVRx’s EPS estimate?
CVRx’s EPS estimate is -0.53.
How many shares outstanding does CVRx have?
CVRx has 26,535,944 shares outstanding.
What happened to CVRx’s price movement after its last earnings report?
CVRx reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.504. Following the earnings report the stock price went down -23.844%.
Which hedge fund is a major shareholder of CVRx?
Currently, no hedge funds are holding shares in CVRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CVRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (42.66% Upside)
$10.50 (42.66% Upside)
Blogger Sentiment
Bullish
CVRX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 207.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-35.42%
12-Months-Change
Fundamentals
Return on Equity
-120.77%
Trailing 12-Months
Asset Growth
-23.04%
Trailing 12-Months
Company Description
CVRx
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
CVRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly constructive operational and commercial picture: strong top-line growth (+20% total, +22% U.S.), margin expansion (87% gross margin), ASP improvement and clear progress on the major clinical trial (BENEFIT-HF) and reimbursement milestones (Category I CPT code). Near-term headwinds are primarily administrative and timing-related (Medicare Advantage prior authorization volatility), plus continued operating losses and elevated operating expense guidance. The positives — revenue acceleration, improving gross margin, clinical trial activation, and reimbursement progress — outweigh the short-term challenges, which management characterizes as addressable and temporary.View all CVRX earnings summariesCVRX Stock 12 Month Forecast
Average Price Target
$10.50
▲(42.66% Upside)
Technical Analysis
Ownership Overview
29.03% Insiders
6.16% Mutual Funds
31.86% Other Institutional Investors
26.72% Public Companies and
Individual Investors